University of California San Francisco
Give to UCSF
Two UCSF scientists – James Gardner, MD, PhD, and Rebeca de Pavia Fróes Rocha, PhD – have received Pew awards for their work in immunology as part of a program that supports promising early-career investigators.
Two new oral polio vaccines will help limit the amount of new polio strains and outbreaks by genetically engineering weakened polio virus in the oral vaccine to reduce reversion to dangerous forms.
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
UCSF faculty members Walter G. Gonzalez and Angela Phillips have been selected as Howard Hughes Medical Institute (HHMI) Freeman Hrabowski Scholars. With up to $8.6 million in support, they will conduct research, create inclusive lab environments, and make a significant impact on the future of science. Both scholars are committed to fostering diversity and promoting scientific breakthroughs.
COVID vaccine efficacy varied by age, BMI, sex, and smoking status, with levels changing over six months in a UCSF-led study. Pfizer and Moderna had higher antibody responses than Johnson & Johnson at one month, but Johnson & Johnson overtook them at six months.
A hepatitis outbreak in children occurred after COVID-19 lockdowns eased in 2022. Sudden exposure to a multitude of viruses upon reopening may have triggered this response in a small group of children.
Thermo Fisher Scientific Inc. and UCSF will accelerate advanced cell therapies for difficult to treat conditions like cancer from a new manufacturing facility.
A clinical trial showed that, rather than removing lymph nodes, leaving them intact could help immunotherapy activate tumor-fighting T cells in the lymph nodes.
Respiratory viral infections pose significant morbidity and mortality to patients with chronic lung diseases like emphysema and COPD, causing exacerbations that drive destruction of normal lung tissue
UCSF researchers found that distributing pro-COVID-19 vaccine information in EDs in English and Spanish increased vaccine acceptance, especially among Latinos and those without primary care physicians.
When we inhale an airborne virus, our lung cells take on the role of immune system first responders. Catera Wilder, PhD, studies the molecular details of this response and how it can go awry, causing the body to damage its own tissue and cells.
Emily Goldberg's lab studies what happens during aging to a particular set of immune cells: those embedded in fat tissue. She hypothesizes that changes to these cells during aging could be key to age-related inflammation.
Angela Phillips, PhD, leads research that could help predict future viruses like COVID and the antibodies we might use to treat them.
Balyn Zaro’s lab investigates the cause and consequence of genetic diversity in the immune system, in hopes that her discoveries can lead to better treatments for all patients.
Researchers have genetically engineered cells to distract antibodies from attacking friendly, but foreign, cells. This could prevent transplants from being rejected.
T-cells can be directed to produce cytokine, a powerful anti-cancer component, when they encounter cancer cells. This holds tremendous promise for cancer immunotherapy.
Researchers have identified specific immune cells that drive deadly heart inflammation in a small fraction of patients treated with powerful cancer immunotherapy drugs.
A new method of comparing massive numbers of CAR-T cells can determine which is most effective and long-lasting against cancer.
Immune checkpoint inhibitors (ICIs) used in cancer care can cause myocarditis, a potentially fatal side effect, and it appears that the adverse cardiac effects may disproportionally impact female patients.
A new diagnostic method that applies machine learning to advanced genomics data from both microbe and host to identify and predict sepsis cases was developed by researchers at UCSF, the Chan Zuckerberg Initiative, and CZ Biohub.
Last month new “bivalent” booster vaccines made by Moderna and Pfizer became available that protect against currently circulating Omicron variants as well as earlier strains of the SARS-CoV-2 virus that causes COVID-19. This Q&A features Joel Ernst, MD, a UCSF professor of medicine whose research aims to understand how pathogens evade the immune system.
A new therapy pulls forward a mutated version of the KRAS protein to help the immune system recognize and destroy cancer cells.
UCSF-led research outlines the comprehensive immune landscape and microbiome of pancreatic cysts as they progress from benign cysts to pancreatic cancer. Their findings could reveal the mechanism of neoplastic progression and provide targets for immunotherapy to inhibit progression or treat invasive disease.
